Effects on the male endocrine system of long-term treatment with gonadotropin-releasing hormone agonists and estrogens in male-to-female transsexuals

Hormone and Metabolic Research

Volumn 38, Issue 3, 2006, Pages 183-187

  Mueller, Andreas ^a   Binder, H ^a   Cupisti, S ^a   Hoffmann, I ^a   Beckmann, M W ^a   Dittrich, R ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adrenal hormones; Estrogen; GnRH analogues; Testis; Transsexuals

Indexed keywords

ANDROGEN; CORTICOSTEROID; ESTRADIOL VALERATE; ESTROGEN; FOLLITROPIN; GLOBULIN; GONADORELIN; GONADOTROPIN ANTAGONIST; HYDROCORTISONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; TESTIS PEPTIDE HORMONE; TESTOSTERONE;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SEXUAL BEHAVIOR; TESTOSTERONE BLOOD LEVEL; TRANSSEXUALISM;

ADOLESCENT; ADULT; AGED; DEHYDROEPIANDROSTERONE SULFATE; ENDOCRINE SYSTEM; ESTRADIOL; ESTROGENS; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME FACTORS; TRANSCORTIN; TRANSSEXUALISM;

EID: 33646236829     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-925198     Document Type: Article

References (33)

1. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab 2001; 86: 5729-5736
2. Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M. Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment; in Japanese. Hinyokika Kiyo 2003; 49: 521-525
3. Eri LM, Haug E, Tveter KJ. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Scand J Clin Lab Invest 1996; 56: 319-325
4. Philip PA, Carmichael J, Tonkin K et al. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 1993; 67: 379-382
5. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566-1572
6. Kitahara S, Umeda H, Yano M et al. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 1999; 46: 659-664
7. Spetz AC, Hammar M, Lindberg B, Spangberg A, Varenhorst E, Scandinavian Prostatic Cancer Group-5 Trial Study. Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001; 166: 517-520
8. Gerber GS, Zagaja GP, Ray PS, Rukstalis DB. Transdermal estrogen in the treatment of hot flushes in men with prostate cancer. Urology 2000; 55: 97-101
9. Fiet J, Dore JC, Go AL, Ojasoo T, Raynaud JP. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy. Prostate 1993; 23: 291-313
10. Ayub M, Levell MJ. Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue. Clin Endocrinol (Oxf) 1990; 32: 329-339
11. Hamburger C. Endocrine treatment of male and female transsexualism. In: Green R, Money J (eds). Transsexualism and Sex Reassignment. Baltimore: Johns Hopkins Press, 1969: 291-307
12. Harry Benjamin International Gender Dysphoria Association. The Harry Benjamin International Gender Dysphoria Association standards of care for gender identity disorders, 6th version (November 17th, 2001). http://www.hbigda.org/ soc.html. Retrieved 2002
13. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88: 3467-3473
14. Levy A, Crown A, Reid R. Endocrine intervention for transsexuals. Clin Endocrinol 2003; 59: 409-418
15. Futterweit W. Endocrine management of transsexual: hormonal profiles of serum prolactin, testosterone, and estradiol. N Y State J Med 1980; 80: 1260-1264
16. Asscheman H, Gooren L, Assies J, Smith J, De Slegte R. Prolactin levels and pituitary enlargement in hormone-treated male to female transsexual people. Clin Endocrinol (Oxf) 1988; 28: 583-588
17. Gooren L, Assies J, Asscheman H, de Slegte R, van Kessel H. Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab 1988; 66: 444-446
18. Asscheman H, Gooren L, Eklund P. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism 1989; 38: 869-873
19. Van Kesteren P, Asscheman H, Megens J, Gooren L. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-342
20. Michel A, Mormont C, Legros J. A psycho-endocrinological overview of transsexualism. Eur J Endocrinol 2001; 145: 365-376
21. Khosla S, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266-2274
22. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5: 98-102
23. Carreau S, Bourguiba S, Marie E. Testicular and blood steroid levels in aged men. Reprod Biol 2004; 4: 299-304
24. Tyrell JB, Aron DC, Forsham PH. Glucocorticoids and adrenal androgens. In: Greenspan FS (ed). Basic and clinical endocrinology, 3rd ed. Englewood Cliffs, New Jersey: Prentice-Hall, 1991: 323-362
25. Gregg DW, Allen MC, Nett TM. Estradiol-induced increase in number of gonadotropin-releasing hormone receptors in cultured ovine pituitary cells. Biol Reprod 1990; 43: 1032-1036
26. Dall'Asta C, Ballare E, Mantovani G et al. Assessing the presence of abnormal regulation of cortisol secretion by membrane hormone receptors: in vivo and in vitro studies in patients with functioning and non-functioning adrenal adenoma. Horm Metab Res 2004; 36: 578-583
27. Miyamura N, Tsutsumi A, Senokuchi H et al. A case of ACTH-independent macronodular adrenal hyperplasia: simultaneous expression of several aberrant hormone receptors in the adrenal gland. Endocr J 2003; 50: 333-340
28. Aedo AR, Landgren BM, Diczfalusy E. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in postmenopausal women. Maturitas 1990; 12: 333-343
29. Kuhl H. Pharmacology of estradiol and estriol. Menopause Rev 2000; 5: 23-44
30. Lin AD, Chen KK, Lin AT et al. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. J Chin Med Assoc 2003; 66: 735-740
31. Adlercreutz H, Tenhunen R. Some aspects of the interaction between natural and synthetic female sex hormones and the liver. Am J Med 1970; 49: 630-648
32. Aldinger K, Ben Menachem Y, Whalen G. Focal nodular hyperplasia of the liver associated with high-dosage estrogens. Arch Intern Med 1977; 137: 357-359
33. Mueller A, Dittrich R, Binder H, Kühnel W, Maltaris T, Hoffmann I, Beckmann MW. High Dose Estrogen Treatment Increases Bone Mineral Density in Male to Female Transsexuals Receiving Gonadotropin-Releasing Hormone Agonist in the Absence of Testosterone. Eur J Endocrinol 2005; 153: 107-113